# Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC

> **NCT07412054** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 234 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab
- **DRUG:** Branched-Chain Amino Acids

## Key facts

- **NCT ID:** NCT07412054
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07412054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07412054, "Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07412054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*